We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-20.83%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$803M
AUM Growth
-$319M
Cap. Flow
-$34M
Cap. Flow %
-4.24%
Top 10 Hldgs %
60.78%
Holding
78
New
17
Increased
17
Reduced
12
Closed
19

Top Buys

Rank Stock Value
1
NCNA
NuCana
NCNA
+$28.4M
2
GILD icon
Gilead Sciences
GILD
+$14.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.4M
4
INCY icon
Incyte
INCY
+$12.2M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.65M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$61.6M
2
AGN
Allergan plc
AGN
+$18.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.09M
4
APLS
Apellis Pharmaceuticals
APLS
+$7.67M
5
EXEL icon
Exelixis
EXEL
+$7.15M

Sector Composition

Rank Sector Weight
1 Healthcare 91.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
51
DELISTED
Otonomy, Inc.
OTIC
$1.89M 0.24%
1,023,865
+36,087
+4% +$85.1K
ANAB icon
52
AnaptysBio
ANAB
$1.6B
$1.59M 0.2%
25,020
-44,595
-64% -$3.32M
SNDX icon
53
Syndax Pharmaceuticals
SNDX
$1.84B
$1.56M 0.19%
350,110
+176,998
+102% +$970K
HSTO
54
DELISTED
Histogen Inc. Common Stock
HSTO
$1.1M 0.14%
3,191
+496
+18% +$385K
PDSB icon
55
PDS Biotechnology
PDSB
$38.1M
$916K 0.11%
142,636
– –
PCRX icon
56
Pacira BioSciences
PCRX
$1.02B
$731K 0.09%
+16,994
New +$793K
APLS
57
DELISTED
Apellis Pharmaceuticals
APLS
$654K 0.08%
49,580
-500,000
-91% -$7.67M
ADAP
58
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-89,919
Closed -$1.22M
AZN icon
59
CALL
AstraZeneca
AZN
$263B
– –
-96,700
Closed -$7.65M
BPMC
60
DELISTED
Blueprint Medicines
BPMC
– –
-51,339
Closed -$4.01M
CLSD
61
DELISTED
Clearside Biomedical
CLSD
– –
-40,461
Closed -$3.73M
CPRX
62
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-1,549,552
Closed -$5.86M
ESPR
63
DELISTED
Esperion Therapeutics
ESPR
– –
-36,599
Closed -$1.62M
EXEL icon
64
Exelixis
EXEL
$13.9B
– –
-403,594
Closed -$7.15M
KURA icon
65
Kura Oncology
KURA
$922M
– –
-247,385
Closed -$4.33M
OCGN icon
66
Ocugen
OCGN
$410M
– –
-34,617
Closed -$1.13M
RYTM icon
67
Rhythm Pharmaceuticals
RYTM
$7B
– –
-159,302
Closed -$4.65M
CYTO
68
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-18
Closed –
KDNY
69
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-37,916
Closed -$1.39M
FSTX
70
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-47,412
Closed -$2.29M
ADMS
71
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-345,756
Closed -$6.92M
ALXN
72
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-65,360
Closed -$9.09M
AGN
73
DELISTED
Allergan plc
AGN
– –
-96,021
Closed -$18.3M
ARQL
74
DELISTED
Arqule Inc
ARQL
– –
-386,271
Closed -$2.19M
OMED
75
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-395,744
Closed -$839K
1 2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2018 Portfolio in Review

As of Q4 2018, Sofinnova Investments held 78 positions worth $803M, down 28% from $1.12B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sofinnova Investments withdrew a net $34M in Q4 2018, closing 19 positions and reducing 12 holdings. Its most notable exit was Allergan plc, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 86% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Gilead Sciences worth $13.3M.

  • Sofinnova Investments's largest Q4 2018 buy was Gilead Sciences: 213,331 shares worth $13.3M.
  • Sofinnova Investments added most to NuCana in Q4 2018, an estimated $28.4M increase.
  • Sofinnova Investments's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $61.6M.
  • Sofinnova Investments fully exited Allergan plc in Q4 2018, selling an estimated $18.3M.
  • Sofinnova Investments's ten largest holdings make up 61% of its $803M portfolio in Q4 2018.
  • Sofinnova Investments opened 17 new positions and closed 19 in Q4 2018.
  • Sofinnova Investments's portfolio value fell 28% quarter-over-quarter to $803M.

Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.